GE to sell Draxis generic MIBI

Dec 20, 2007

Canadian radiopharmaceutical developer Draxis Health of Mississauga, Ontario, has signed a deal with GE Healthcare giving the Chalfont St. Giles, U.K.-based company rights to sell Draxis generic technetium-99m sestamibi in the U.S.

Draxis Health's DraxImage radiopharmaceutical unit has given GE exclusive rights to sell DraxImage Sestamibi in the U.S. and Canada once patent protection expires for Cardiolite, technetium sestamibi nuclear cardiology radiopharmaceutical marketed by Bristol-Myers Squibb Medical Imaging of North Billerica, MA. GE has also agreed to purchase technetium sestamibi exclusively from DraxImage.

DraxImage must also receive U.S. and Canadian regulatory approvals for its version of technetium sestamibi before commercial sales can begin. DraxImage submitted an abbreviated new drug application (ANDA) to the U.S. Food and Drug Administration in February 2007, and has also made regulatory filings with European and Canadian agencies.

Draxis Health's earnings take Q3 hit, November 1, 2007

Draxis Health posts second-quarter dip, August 10, 2007

Confirma expands partnership with GE, December 18, 2007

RCT issues license to GE, December 18, 2007

$ChatGPT powered by GPT-4 and using DALL-E−3 was asked to generate an image for teaching purposes that demonstrated: a nuclear medicine bone scan with skeletal metastases (top left); coronary artery disease (top right); an F-18 FDG-PET scan of the brain with Alzheimer's disease (bottom left); and an x-ray showing a fracture (bottom right). These are misleading for educational purposes and for patients who may be searching for information. Image and caption courtesy of Radiography.$